SAN FRANCISCO – Pillsbury is advising Genomic Health, Inc. in connection with its $2.8 billion combination with Exact Sciences Corporation. The transaction, which is expected to be completed by the end of 2019, is subject to customary closing conditions, including regulatory approvals.

The combination will combine two leading cancer diagnostics companies. Genomic Health’s Oncotype DX gene expression tests are used to guide treatment decisions for cancer patients, and Exact Sciences’ Cologuard is a leading diagnostic test for colorectal cancer screening. Pillsbury has represented Genomic Health since its inception in 2000 and helped the company go public in 2005.

The cross-office Pillsbury team advising Genomic Health was led by San Francisco Corporate partner Stanton Wong and included Corporate partners Justin Hovey and Gabriella Lombardi, special counsel Mustapha Parekh, counsel Deborah Carrillo and associates Jamin Agosti, Mediha Ali and Jessica Dabiri; Tax Partner Julie Divola; Executive Compensation & Benefits partners Christine Richardson and Jonathan Ocker and associate Ben Gibbs, and Technology Transactions partner Michael Heuga.